DARE - セルリアン・ファ―マ (Dare Bioscience Inc.) セルリアン・ファ―マ

 DAREのチャート


 DAREの企業情報

symbol DARE
会社名 Dare Bioscience Inc (セルリアン・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 デア・バイオサインス(Dare Bioscience Inc.)(旧名:Cerulean Pharma Inc)は医療会社である。同社は女性のリプロダクティブ・ヘルスにおける製品の開発・商品化に従事する。主要製品候補は、臨床段階の非ホルモン性避妊リングであるオバプレンである。同社は性交の時に介入を必要とせず、複数週間の使用にわたって保護を提供するためにオバプレンを開発する。そのオバプレンには、精液への部分的な障壁を作り出すリングの中心に透過性のメッシュを持つカスタムの膣内リングデザインがあり、リングを介して局所的に作用する精子形成剤を放出するメカニズムがある。これらの2つの相補的アプローチの組み合わせは、効果的な障壁選択肢、横隔膜、および経口ピル、パッチおよび膣リングなどの短時間作用性ホルモン選択肢と一致する魅力的な避妊効果結果をもたらす。   セルリアン・ファ―マは、米国の治療薬開発会社。臨床病期の腫瘍学に焦点を当て、がんや他の疾患向けに、ナノテクノロジ―ベ―スの治療薬の開発を手掛ける。主な製品候補は、第二段階の臨床開発中であるCRLX101のほか、強力かつ耐久性のある抗がん剤CRLX301などがある。本社はマサチュ―セッツ州ケンブリッジ。   Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. The company's mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.
本社所在地 3655 Nobel Drive Suite 260 San Diego CA 92122 USA
代表者氏名 Roger L. Hawley ロジャー・ホーリー
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-926-7655
設立年月日 38657
市場名 NASDAQ Small Cap
ipoyear 2014年
従業員数 5人
url www.ceruleanrx.com
nasdaq_url https://www.nasdaq.com/symbol/dare
adr_tso
EBITDA EBITDA(百万ドル) -9.09586
終値(lastsale) 0.98
時価総額(marketcap) 11193717.78
時価総額 時価総額(百万ドル) 11.23598
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) -1.21054
当期純利益 当期純利益(百万ドル) -22.00885
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Dare Bioscience Inc revenues was not reported. Net loss increased from $742K to $11.2M. Higher net loss reflects Impairment of goodwill increase from $0K to $5.2M (expense) Research and development expenses increase from $31K to $3.3M (expense) General and administrative increase from $677K to $2.5M (expense).

 DAREのテクニカル分析


 DAREのニュース

   Dare Bioscience Inc. (DARE): Why Is The Stock Strong?  2022/04/04 18:00:00 Marketing Sentinel
Dare Bioscience Inc. (NASDAQ:DARE) has a beta value of 1.39 and has seen 2.28 million shares traded in the recent trading session. The company, currently valued at $114.11M, closed the recent trade at $1.78 per share which meant it gained $0.07 on the day or 4.39% during that session. The DARE stock price is -41.01% … Dare Bioscience Inc. (DARE): Why Is The Stock Strong? Read More »
   Dare Bioscience Inc. (NASDAQ: DARE) Offers Great Upside  2022/03/31 18:00:00 Stocks Register
Dare Bioscience Inc. (NASDAQ:DARE) shares, rose in value on Thursday, March 31, with the stock price up by 5.78% to the previous day’s close as strong demand from buyers drove the stock to $1.55. Actively observing the price movement in the recent trading, the stock is buoying the session at $1.47, falling within a range … Dare Bioscience Inc. (NASDAQ: DARE) Offers Great Upside Read More »
   Organon Inks Licensing Pact For Daré Bioscience''s Bacterial Vaginosis Treatment  2022/03/31 17:22:05 Benzinga
Organon & Co (NYSE: OGN ) will license global rights to Daré Bioscience Inc''s (NASDAQ: DARE ) Xaciato (clindamycin phosphate vaginal gel, 2%). Xaciato is an FDA-approved medication for treating bacterial vaginosis (BV) in females 12 years of age and older. It has received both Qualified Infectious Disease Product (QIDP) … Full story available on Benzinga.com
   Dare Bioscience GAAP EPS of -$0.63 misses by $0.03 (NASDAQ:DARE)  2022/03/31 13:24:08 Seeking Alpha
Dare Bioscience press release (DARE): FY GAAP EPS of -$0.63 misses by $0.03.Cash and cash equivalents of $51.7 million at December 31, 2021, compared to $4.7 million at December…
   Earnings Scheduled For March 31, 2022  2022/03/31 09:25:32 Benzinga
Companies Reporting Before The Bell • Trevena (NASDAQ: TRVN ) is likely to report earnings for its fourth quarter. • Perma-Fix Envirn Servs (NASDAQ: PESI ) is likely to report earnings for its fourth quarter. • Recruiter.Com Group (NASDAQ: RCRT ) is projected to report quarterly loss at $0.38 per share on revenue of $8.77 million. • SPDR Select Sector Fund - Consumer Discretionary (NYSE: XLY ) is likely to report quarterly loss at $0.01 per share on revenue of $29.80 million. • Welltower (NYSE: WELL ) is projected to report quarterly loss at $0.03 per share on revenue of $112.79 million. • Renalytix (NASDAQ: RNLX ) is projected to report quarterly loss at $0.17 per share on revenue of $500.00 thousand. • 1847 Goedeker (AMEX: GOED ) is projected to report quarterly earnings at $0.05 per share on revenue of $145.00 million. • Celsion (NASDAQ: CLSN ) is likely to report quarterly loss at $0.90 per share on revenue of $120.00 thousand. • Acacia Research (NASDAQ: ACTG ) is likely to report quarterly loss at $0.
   Dare Bioscience Inc. (DARE): Why Is The Stock Strong?  2022/04/04 18:00:00 Marketing Sentinel
Dare Bioscience Inc. (NASDAQ:DARE) has a beta value of 1.39 and has seen 2.28 million shares traded in the recent trading session. The company, currently valued at $114.11M, closed the recent trade at $1.78 per share which meant it gained $0.07 on the day or 4.39% during that session. The DARE stock price is -41.01% … Dare Bioscience Inc. (DARE): Why Is The Stock Strong? Read More »
   Dare Bioscience Inc. (NASDAQ: DARE) Offers Great Upside  2022/03/31 18:00:00 Stocks Register
Dare Bioscience Inc. (NASDAQ:DARE) shares, rose in value on Thursday, March 31, with the stock price up by 5.78% to the previous day’s close as strong demand from buyers drove the stock to $1.55. Actively observing the price movement in the recent trading, the stock is buoying the session at $1.47, falling within a range … Dare Bioscience Inc. (NASDAQ: DARE) Offers Great Upside Read More »
   Organon Inks Licensing Pact For Daré Bioscience''s Bacterial Vaginosis Treatment  2022/03/31 17:22:05 Benzinga
Organon & Co (NYSE: OGN ) will license global rights to Daré Bioscience Inc''s (NASDAQ: DARE ) Xaciato (clindamycin phosphate vaginal gel, 2%). Xaciato is an FDA-approved medication for treating bacterial vaginosis (BV) in females 12 years of age and older. It has received both Qualified Infectious Disease Product (QIDP) … Full story available on Benzinga.com
   Dare Bioscience GAAP EPS of -$0.63 misses by $0.03 (NASDAQ:DARE)  2022/03/31 13:24:08 Seeking Alpha
Dare Bioscience press release (DARE): FY GAAP EPS of -$0.63 misses by $0.03.Cash and cash equivalents of $51.7 million at December 31, 2021, compared to $4.7 million at December…
   Earnings Scheduled For March 31, 2022  2022/03/31 09:25:32 Benzinga
Companies Reporting Before The Bell • Trevena (NASDAQ: TRVN ) is likely to report earnings for its fourth quarter. • Perma-Fix Envirn Servs (NASDAQ: PESI ) is likely to report earnings for its fourth quarter. • Recruiter.Com Group (NASDAQ: RCRT ) is projected to report quarterly loss at $0.38 per share on revenue of $8.77 million. • SPDR Select Sector Fund - Consumer Discretionary (NYSE: XLY ) is likely to report quarterly loss at $0.01 per share on revenue of $29.80 million. • Welltower (NYSE: WELL ) is projected to report quarterly loss at $0.03 per share on revenue of $112.79 million. • Renalytix (NASDAQ: RNLX ) is projected to report quarterly loss at $0.17 per share on revenue of $500.00 thousand. • 1847 Goedeker (AMEX: GOED ) is projected to report quarterly earnings at $0.05 per share on revenue of $145.00 million. • Celsion (NASDAQ: CLSN ) is likely to report quarterly loss at $0.90 per share on revenue of $120.00 thousand. • Acacia Research (NASDAQ: ACTG ) is likely to report quarterly loss at $0.
   Dare Bioscience Inc. Shares Close the Week 22.6% Lower - Weekly Wrap  2021/01/29 22:30:00 Kwhen Finance
Dare Bioscience Inc. shares closed this week 22.6% lower than it did at the end of last week. The stock is currently up 68.7% year-to-date, up 91.5% over the past 12 months, and down 5.8% over the past five years. This week, the Dow Jones Industrial Average fell 3.3%, and the S&P 500 fell 3.3%. Trading Activity Shares traded as high as $3.01 and as low as $2.00 this week.Shares closed 2e+1% below its 52-week high and 2e+2% above its 52-week low.Trading volume this week was 16.3% lower than the 10-day average and 48.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 6.0% lower than its 5-day moving average, 17.8% higher than its 20-day moving average, and 71.3% higher than its 90-day moving average. Market Comparative Performance The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock priceperformance year-to-date beats the peer average by 33.5% The company's stock price performance over the past 12 months lags the peer average by -28.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Dare Bioscience Inc. Shares Close the Week 102.8% Higher - Weekly Wrap  2021/01/22 22:30:00 Kwhen Finance
Dare Bioscience Inc. shares closed this week 102.8% higher than it did at the end of last week. The stock is currently up 117.9% year-to-date, up 71.8% over the past 12 months, and up 22.2% over the past five years. This week, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 1.9%. Trading Activity Shares traded as high as $3.85 and as low as $1.41 this week.Shares closed 3% below its 52-week high and 3e+2% above its 52-week low.Trading volume this week was 50.4% lower than the 10-day average and 37.1% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock priceperformance year-to-date beats the peer average by 97.6% The company's stock price performance over the past 12 months lags the peer average by -46.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Dare Bioscience Inc. Shares Close the Week 24.8% Higher - Weekly Wrap  2020/12/24 22:30:00 Kwhen Finance
Dare Bioscience Inc. shares closed this week 24.8% higher than it did at the end of last week. The stock is currently up 72.0% year-to-date, up 61.3% over the past 12 months, and down 62.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $1.48 and as low as $1.20 this week.Shares closed 2e+1% below its 52-week high and 8e+1% above its 52-week low.Trading volume this week was 5.7% higher than the 10-day average and 25.2% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's price-earnings ratio is the same as its average peer. The company's performance over the last 1 year lags its average peer by -31.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セルリアン・ファ―マ DARE Dare Bioscience Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)